ELANElanco Animal Health Inc

Upcoming Earnings

We were not able to find an announced earnings date for this symbol yet. Check back again later

Company Info

CEO

Jeffrey N. Simmons

Location

Indiana, USA

Exchange

NYSE

Website

https://elanco.com

Summary

Elanco Animal Health Incorporated offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks.

Company Info

CEO

Jeffrey N. Simmons

Location

Indiana, USA

Exchange

NYSE

Website

https://elanco.com

Summary

Elanco Animal Health Incorporated offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks.

AI Insights for ELAN
5 min read

Quick Summary

Elanco Animal Health Inc. is a U.S.-based animal health company focused on medicines, vaccines, parasiticides, and related products for pets and farm animals. The company sells products that help prevent and treat diseases in companion animals, including dogs and cats, with a particular emphasis on parasite control, dermatology, allergy, vaccines, and broader pet wellness. It also serves livestock producers, including beef and dairy farmers, with products intended to improve animal health, productivity, and disease prevention. Its customers include third-party distributors, veterinarians, farm animal producers, clinics, and other animal health channels. The company operates in the pharmaceutical products industry and is positioned as a diversified animal health manufacturer rather than a human pharmaceutical company.

Strengths

•

Elanco’s main strength is its broad animal health portfolio across both companion animals and livestock.

•

This diversification gives the company exposure to resilient pet healthcare spending as well as farm animal productivity needs.

•

The company has recognizable capabilities in parasiticides, vaccines, dermatology, allergy therapies, and dairy health solutions.

•

Its distribution relationships with veterinarians, third-party distributors, and animal producers create a commercial platform for new launches.

•

The company is also actively investing in innovation, manufacturing capacity, acquisitions, and restructuring efforts intended to improve long-term growth and profitability.

Key Risks

•

Elanco faces regulatory risk because animal health products often require approvals, safety monitoring, and compliance with changing standards in multiple countries.

•

Product safety controversies, warning labels, lawsuits, or recalls could damage revenue, reputation, and veterinarian trust.

•

The company also faces competitive risk from larger or more profitable animal health rivals such as Zoetis, Merck Animal Health, Boehringer Ingelheim, IDEXX, and Virbac.

•

Execution risk is meaningful because Elanco must integrate acquisitions, ramp new products, expand manufacturing, restructure operations, and reduce leverage while maintaining service levels.

What to Watch

In the most recent reported quarter, Elanco generated $1.368 billion in revenue and $798 million in gross profit, indicating a substantial gross margin base in its animal health portfolio.
Operating income was $115 million and net income was $54 million, while both basic and diluted EPS were $0.11.
The quarter’s news backdrop included portfolio expansion through the reported acquisition of AHV International, which strengthens Elanco’s dairy health exposure.
The company also gained USDA approval for Befrena, a canine allergy therapy, which supports its companion animal dermatology and allergy pipeline.
Additional events around the period included U.S. availability of Credelio Quattro, an expansion project at the Huningue, France tablet site, and communication of a 2026 to 2028 growth plan focused on innovation revenue, EBITDA growth, free cash flow, leverage reduction, and cost savings.

Price Drivers

•

ELAN’s stock price is likely being driven by a combination of revenue growth expectations, profitability improvement, product approvals, debt and leverage concerns, and investor confidence in management’s multi-year plan.

•

The company reported Q3 2026 operating revenue of $1.368 billion, gross profit of $798 million, operating income of $115 million, net income of $54 million, and diluted EPS of $0.11, which suggests positive but still modest profitability.

•

Valuation metrics show a market capitalization of about $11.3 billion, price-to-book of 1.7177, EV-to-revenue of 2.9292, and EV-to-EBITDA of 19.5538, so investors appear to be paying for expected future improvement rather than current earnings alone.

•

The beta of 1.705 indicates the stock may move more sharply than the broader market, especially around news on approvals, lawsuits, guidance, and quarterly results.

•

Recent price drivers also include reported acquisitions, product launches, manufacturing expansion, the 2026 to 2028 growth plan, and concerns about litigation or safety controversies related to certain products.

Recent News

•

Recent news items indicate that Elanco acquired Dutch dairy health firm AHV International and gained USDA approval for Befrena, a canine allergy therapy.

•

The company also announced U.S. availability of Credelio Quattro, a monthly chewable product for dogs that offers broad protection against fleas, ticks, heartworms, roundworms, hookworms, and tapeworms.

•

Elanco broke ground on an expansion at its Huningue, France tablet production site to increase capacity for pet health products and add production, storage, and quality-control space.

•

The company outlined a 2026 to 2028 growth plan targeting mid-single-digit organic revenue growth, high-single-digit adjusted EBITDA growth, low-double-digit EPS growth, leverage below 3x by 2027, and $200 million to $250 million in savings by 2030.

•

News flow has also included past concerns around shareholder litigation, class-action allegations, Seresto safety controversy, Zenrelia warning concerns, and investor debate over whether new product launches can offset risk.

Market Trends

•

The animal health market is supported by long-term pet humanization, higher spending on companion animal care, and demand for preventive medicines.

•

Pet owners increasingly view dogs and cats as family members, which helps sustain spending on parasiticides, allergy care, dermatology, pain management, vaccines, and diagnostics.

•

Livestock health demand is influenced by global protein consumption, dairy productivity needs, biosecurity concerns, sustainability requirements, and producer profitability.

•

At the same time, the industry faces pressure from regulation, safety scrutiny, competition, generic alternatives, and changing views on antimicrobial use in food animals.

•

Broader equity-market trends, interest rates, risk appetite, and investor preference for profitable healthcare businesses can also affect ELAN because the stock has a high beta and depends on confidence in future execution.

AI-generated summary for educational purposes only. Not investment advice. Always do your own research before investing.

Community Research

Research from investors like you

Be the first to share your analysis on ELAN

Help fellow investors make informed decisions by sharing your research on fundamentals, catalysts, and outlook.

Topics: Company overview • Products • Competitors • Strengths & Risks

Symbol's posts

No more topics to show